Aprea Therapeutics, Inc. Shareholders' Equity
Aprea Therapeutics, Inc. (APRE) had Shareholders' Equity of $38.47 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-12
- 2026-06-30: Stockholders' Equity Attributable to Parent $38.47M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $41.59M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $12.44M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $10.91M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $38.47M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $41.59M 10-Q · filed 2026-08-12 |
| 2025-12-31 | $12.44M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $10.91M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $13.41M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $15.55M 10-Q · filed 2026-08-12 |
| 2024-12-31 | $19.31M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $21.95M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $25.56M 10-Q · filed 2025-11-12 |
| 2024-03-31 | $28.92M 10-Q · filed 2025-11-12 |
| 2023-12-31 | $16.95M 10-K · filed 2026-03-16 |
| 2023-09-30 | $20.29M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $23.42M 10-Q · filed 2024-11-07 |
| 2023-03-31 | $26.48M 10-Q · filed 2024-11-07 |
| 2022-12-31 | $25.64M 10-K · filed 2025-03-25 |
| 2022-09-30 | $26.63M 10-Q · filed 2023-11-09 |
| 2022-06-30 | -$35.78M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $43.59M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $49.51M 10-K · filed 2024-03-26 |
| 2021-09-30 | $53.42M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $60.95M 10-Q · filed 2022-11-09 |
| 2021-03-31 | $69.15M 10-Q · filed 2022-11-09 |
| 2020-12-31 | $77.40M 10-K · filed 2024-03-26 |
| 2020-09-30 | $89.02M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $100.12M 10-Q · filed 2021-11-08 |
| 2020-03-31 | $113.35M 10-Q · filed 2021-08-12 |
| 2019-12-31 | $124.24M 10-K · filed 2023-03-30 |
| 2019-09-30 | -$70.80M 10-Q · filed 2020-11-06 |
| 2019-06-30 | -$61.85M 10-Q · filed 2020-11-06 |
| 2019-03-31 | -$56.82M 10-Q · filed 2020-08-11 |
| 2018-12-31 | -$51.44M 10-K · filed 2022-03-15 |
| 2018-09-30 | -$47.47M 10-Q · filed 2019-11-14 |
| 2018-06-30 | -$44.48M 10-Q · filed 2019-11-14 |
| 2017-12-31 | -$35.77M 10-K · filed 2021-03-16 |
| 2016-12-31 | -$21.47M 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |